Amlodipine Besylate Market Seen Soaring 4.5% Growth to Reach USD 410 Million by 2030, Projects Univdatos Market Insights
- Vikas Kumar
- November 17, 2023
- HEALTHCARE, NEWS
- Amlodipine Besylate, Amlodipine Besylate Market, Amlodipine Besylate Market analysis, Amlodipine Besylate Market forecast, Amlodipine Besylate Market growth, Amlodipine Besylate Market share, Amlodipine Besylate Market trends
- 0 Comments
Key Highlights of the Report:
- Growing demand in the healthcare sector: The amlodipine besylate market is experiencing significant growth due to increasing demand in the healthcare sector, driven by growing concerns over widespread alcohol and tobacco consumption.
- Rise in pharmaceutical market: There has been growing demand for pharmaceuticals owing to increased incidences of bad lifestyle, and unhealthy food consumption.
- FDA-approved indications: The FDA-approved usage of amlodipine besylate for treating multiple indications including hypertension and chronic stable angina.
According to a new report by Univdatos Market Insights, Amlodipine Besylate Market is expected to reach USD 410 Million in 2030 by growing at a CAGR of 4.5%. Amlodipine, sold under the brand name Norvasc, is an oral voltage-dependent L-type calcium channel blocker with the chemical constitution of dihydropyridine. Amlodipine blocks the initial entry of calcium and has the longest half-life of 30 to 50 hours compared to other drugs of similar category. Amlodipine besylate is generally used to treat heart disorders, including high blood pressure and chronic stable angina. While considering dosage types, the 10 mg dosage type held the maximum share while comparing other dosage types of amlodipine besylate owing to its higher effectiveness. Several factors are contributing to the growth of amlodipine besylate including the increased consumption of alcohol and tobacco, the surge in awareness programs regarding heart diseases, and rising investments in cardiology departments are driving the growth of amlodipine besylate. Apart from these factors, rising strategic collaborations are leading the market of amlodipine besylate in this forecast period. For instance, in September 2021, U.S.-based Azurity Pharmaceuticals Inc. acquired Arbor Pharmaceuticals LLC for, high-value goods to address the requirements of patients with chronic illnesses.
Access Sample PDF Here- https://univdatos.com/get-a-free-sample-form-php/?product_id=47211
The report suggests that the Rising Research on Cardiovascular Diseases is one of the major factors driving the growth of the amlodipine besylate market during the forthcoming years. Amlodipine Besylate has gained support in terms of research and development in pharmaceutical industries. Money is an essential factor for gaining prominence in the market and cardiovascular disease research is attracting a huge load of money investments. This expenditure is driving the market for the development of new technological advancements in amlodipine besylate. In recent years, there has been an increasing number of launches, FDA approvals, and an increasing number of technological advancements focused on cardiovascular diseases. For instance, in February 2022, CMP Pharma received FDA approval for its Norliqva (Amlodipine) Oral Solution which is the first and only medication of its kind to treat heart diseases. It also provides hope for patients to get better care and support through amlodipine besylate, also it can serve as a doorway of opportunities for offering better treatment options in the future.
FDA-approved Indications-
In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the report of approved indications for amlodipine besylate. According to the report, here are certain indications approved by the FDA for the drug-
- Hypertension – Amlodipine stands superior amongst other antihypertensive agents. For hypertension, amlodipine besylate can be used alone or in combination with other drugs.
- Chronic Stable Angina – Amlodipine is indicated for the treatment of chronic stable angina by the FDA. In this case as well, amlodipine be used alone or in combination with other drugs.
- Vasospastic Angina – Amlodipine besylate is indicated to treat vasospastic angina by the FDA.
- Angiographically Documented Coronary artery disease (CAD) – For recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine is indicated to reduce the risk of a coronary revascularization procedure and to reduce the risk of hospitalization from angina by the FDA.
Conclusion
The global amlodipine besylate market is a rapidly growing field, with advancements in technology leading to improved outcomes for patients with cardiovascular disorders. The global amlodipine besylate market is expected to continue to grow in the coming years, as new technologies are developed. Overall, the global amlodipine besylate market represents a significant opportunity for pharmaceutical industries, which are making strategic alliances to design an effective drug for cardiac disease treatment. With continued research and development, it is likely that even more treatments will become available in the future, leading to improved outcomes for patients through amlodipine besylate.
Key Offerings of the Report
Market Size, Trends, & Forecast by Revenue | 2023−2030
Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
Market Segmentation – A detailed analysis by Dosage Type, Application, and Region
Competitive Landscape – Top Key Vendors and Other Prominent Vendors
